Table 1. Response of underlying cancer to treatment with EGFR inhibition in reported cases of trichomegaly. All cases associated with trichomegaly occurred in females and associated no progression of the tumor (either stable disease or an objective response of the cancer).

Publication	Patient age and gender	EGFR inhibitor	Effect on Eye lashes	Type of Cancer	Response of Cancer	Time from starting EGFR inhibitor to development of trichomegaly
Braideth F et al. 2008	57 F	Erlotinib	Trichomegaly	Lung	Major response	N/A
Lane K et al. 2007	70 F	Erlotinib	Trichomegaly	Lung	Durable stable disease and symptomatic improvement	Several months
Zhang G et al. 2007	Case 1 :58 F	Gefitinib& Erlotinib	Trichomegaly	Lung	Stable disease or better	N/A
Zhang G et al. 2007	Case 2: 87 F	Gefitinib	Trichomegaly	Lung	Stable disease or better	8 months
Carser JE et al. 2996	61 F	Erlotinib	Trichomegaly	Lung	Stable disease and symptomatic improvement	3 months
Bouche O et al. 2005	74 F	Cetuximab	Trichomegaly	Rectal	Stable disease	5 months
Dueland S et al. 2003	26 F	Cetuximab	Trichomegaly	Colon	Tumor response (47% shrink)	10 weeks
Pascual JC et al. 2004	51 F	Gefitinib	Trichomegaly	Lung	Significant response	7 weeks
Garibaldi DC et al. 2007	49 M	Cetuximab	Maderosis	Colon	Tumor progression	weeks